Tuesday's Small-Cap Winners & Losers
Small-cap stocks underperformed the major indices for the second straight session, as several small health care names took their lumps.
Drugmaker Acusphere (ACUS), of Watertown, Mass., lost 11% to $2.26, after agreeing to sell $20 million in stock and warrants to institutional investors under an existing shelf registration. Net proceeds are expected at around $18.7 million.
Geron (GERN) also took a hit after failing to announce big news on its GRN163L cancer treatment. The California-based company only reported that phase I/II testing has yielded positive results in pharmacokinetics and tolerability. Shares tumbled 8.5% to $7.97.
Cyberonics (CYBX), which makes devices for epilepsy treatment, slid 7.8% to $16.59 on disappointing financials. The Houston-based company's loss more than doubled to 42 cents a share -- 7 cents worse than the mean Street target from Thomson Financial. Revenue came in just shy of consensus.Geron and Cyberonics pressured the Russell 2000, which was recently off 0.9%, or 7.83 points, to 825.35. But a few other Russell 2000 components -- namely, Pier 1 Imports (PIR), Robbins & Myers (RBN) and Take-Two Interactive Software (TTWO) -- jumped on analyst upgrades. Goldman Sachs raised home-furnishings retailer Pier 1 to buy from hold, saying a turnaround might be around the corner. Ohio's Robbins, which makes equipment and systems for a variety of industries, was likewise upped to buy at KeyBanc Capital Market. And Take-Two was upgraded by both JPMorgan and Kaufman Brothers on the heels of last night's earnings report. Pier 1, Robbins and New York-based Take-Two were all recently trading up 4.7% or more, the latter two in support of the S&P SmallCap 600. Still, the index was down 0.8% at 428.35. Elsewhere in positive territory, VirtualScopics (VSCP), of Rochester, N.Y., soared 24% to $1.40, after inking a five-year clinical-trials-services deal with a "leading" biotech company. Financial terms weren't disclosed. Filtration-products maker MFRI (MFRI) quintupled its first-quarter per-share earnings compared with the year-ago period. The company reported earnings of 15 cents a share, beating two analysts' estimates by a nickel. And Georgia's Exide Technologies (XIDE) sharply narrowed its fiscal fourth-quarter loss to 35 cents a share. A year ago, the lead-acid-batteries maker lost $2.98 a share. Shares of Illinois-based MFRI were leaping $3.12, or 13%, to $26.52. Exide advanced 8.1% to $8.25.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV